Amneal Pharmaceuticals (NYSE:AMRX) Downgraded by Royal Bank of Canada to Sector Perform

Share on StockTwits

Royal Bank of Canada cut shares of Amneal Pharmaceuticals (NYSE:AMRX) from an outperform rating to a sector perform rating in a research note released on Thursday, BenzingaRatingsTable reports. Royal Bank of Canada currently has $6.00 target price on the stock, down from their previous target price of $11.00.

AMRX has been the subject of a number of other reports. Piper Jaffray Companies set a $92.00 price objective on Wintrust Financial and gave the stock a buy rating in a research report on Monday, July 8th. Raymond James lifted their price objective on S&P Global from $226.00 to $246.00 and gave the stock an outperform rating in a report on Wednesday, July 10th. Zacks Investment Research cut ExlService from a hold rating to a sell rating in a report on Wednesday, July 10th. ValuEngine cut Whiting USA Trust II from a hold rating to a sell rating in a report on Tuesday, May 7th. Finally, SunTrust Banks began coverage on Zoetis in a report on Tuesday, March 19th. They set a hold rating and a $100.00 price objective for the company. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $13.71.

NYSE:AMRX opened at $3.70 on Thursday. The stock’s 50 day moving average price is $7.12. The stock has a market cap of $1.11 billion, a P/E ratio of 3.89, a PEG ratio of 0.28 and a beta of 1.51. The company has a quick ratio of 1.37, a current ratio of 2.11 and a debt-to-equity ratio of 3.44. Amneal Pharmaceuticals has a 52-week low of $3.69 and a 52-week high of $24.48.

Amneal Pharmaceuticals (NYSE:AMRX) last released its quarterly earnings results on Thursday, May 9th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.07). The firm had revenue of $446.00 million for the quarter, compared to analysts’ expectations of $438.18 million. Amneal Pharmaceuticals had a positive return on equity of 32.14% and a negative net margin of 3.75%. The business’s revenue was up 4.9% on a year-over-year basis. Equities research analysts predict that Amneal Pharmaceuticals will post 0.74 EPS for the current fiscal year.

In other Amneal Pharmaceuticals news, SVP Pradeep Bhadauria acquired 7,000 shares of the stock in a transaction dated Wednesday, May 15th. The stock was acquired at an average price of $8.48 per share, with a total value of $59,360.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Joseph Todisco acquired 15,000 shares of the stock in a transaction dated Monday, May 13th. The stock was acquired at an average cost of $9.88 per share, with a total value of $148,200.00. The disclosure for this purchase can be found here. Insiders have acquired 41,000 shares of company stock valued at $387,300 in the last three months. 26.34% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in the company. Bessemer Group Inc. acquired a new position in shares of Amneal Pharmaceuticals during the fourth quarter worth about $34,000. Quantamental Technologies LLC lifted its stake in shares of Amneal Pharmaceuticals by 34.0% during the first quarter. Quantamental Technologies LLC now owns 6,700 shares of the company’s stock worth $95,000 after purchasing an additional 1,700 shares in the last quarter. Meeder Asset Management Inc. lifted its stake in shares of Amneal Pharmaceuticals by 785.6% during the first quarter. Meeder Asset Management Inc. now owns 11,664 shares of the company’s stock worth $166,000 after purchasing an additional 10,347 shares in the last quarter. First Mercantile Trust Co. lifted its stake in shares of Amneal Pharmaceuticals by 40.9% during the first quarter. First Mercantile Trust Co. now owns 11,932 shares of the company’s stock worth $169,000 after purchasing an additional 3,461 shares in the last quarter. Finally, Amalgamated Bank acquired a new position in shares of Amneal Pharmaceuticals during the fourth quarter worth about $174,000. 36.05% of the stock is owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Article: How is Preferred Stock Different from Common Stock?

Analyst Recommendations for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Graft  Price Hits $0.0021
Graft Price Hits $0.0021
Arbidex  Trading Down 14.3% Over Last 7 Days
Arbidex Trading Down 14.3% Over Last 7 Days
ShowHand  Reaches Market Cap of $23,094.00
ShowHand Reaches Market Cap of $23,094.00
CloakCoin One Day Trading Volume Reaches $9,915.00
CloakCoin One Day Trading Volume Reaches $9,915.00
Brokerages Set TransDigm Group Incorporated  Price Target at $540.42
Brokerages Set TransDigm Group Incorporated Price Target at $540.42
$159.33 Million in Sales Expected for Global Eagle Entertainment Inc  This Quarter
$159.33 Million in Sales Expected for Global Eagle Entertainment Inc This Quarter


 
© 2006-2019 Zolmax.